Introduction
Data and methods
Study participants
Imaging examinations and methods
Triple evaluation method
Pathological evaluation
Statistical analysis
Results
General clinical data
All patients | Basal-like | HER2+/ER- | Luminal B | Luminal B(HER2+) | Luminal A | |
---|---|---|---|---|---|---|
N (%) | 143 | 40 | 30 | 32 | 32 | 9 |
Median age (range) | 50 (27,73) | 50 (28,70) | 54 (36,73) | 49 (27,61) | 47 (32,68) | 47 (35,64) |
T1 | 36 | 11 | 8 | 7 | 10 | 0 |
T2 | 91 | 24 | 20 | 22 | 19 | 6 |
T3 | 16 | 5 | 2 | 3 | 3 | 3 |
Stage II | 109 | 36 | 21 | 20 | 25 | 7 |
Stage III | 34 | 4 | 9 | 12 | 7 | 2 |
Premenopause | 77 | 20 | 13 | 17 | 22 | 5 |
Postmenopausal | 66 | 20 | 17 | 15 | 10 | 4 |
Chemotherapy successful cases | 132 | 35 | 30 | 28 | 30 | 9 |
Chemotherapy failure case | 11 | 5 | 0 | 4 | 2 | 0 |
Analysis of related factors between clinical and postoperative pathology
MP grading | B | SE | Wald | ρ | OR | 95% confidence interval | ||
---|---|---|---|---|---|---|---|---|
Lower limit | Upper limit | |||||||
Clinic | The tumor is reduced during palpation. | -3.082 | 1.805 | 2.914 | .088 | .046 | .001 | 1.578 |
There is no change in the size of tumor during palpation. | -2.903 | 2.245 | 1.672 | .196 | .055 | .001 | 4.468 | |
The tumor is soft during palpation. | 1.272 | .813 | 2.445 | .118 | 3.567 | .725 | 17.565 | |
The tumor is hard during palpation. | 22.247 | 2.838 | 61.438 | .000 | 4,591,041,665.454 | 17,616,881.500 | 1,196,446,917,928.918 | |
Ultrasound | The tumor is reduced based on ultrasound. | 2.292 | 1.754 | 1.708 | .191 | 9.891 | .318 | 307.591 |
There is no change in the size of tumor based on ultrasound. | 2.111 | 2.252 | .879 | .348 | 8.260 | .100 | 682.047 | |
The tumor blood flow shows progress based on ultrasound. | 2.561 | 1.285 | 3.971 | .046 | 12.949 | 1.043 | 160.741 | |
The tumor blood flow does not reduce based on ultrasound. | .582 | .619 | .884 | .347 | 1.790 | .532 | 6.022 | |
The preoperative curve is double inflow type. | -2.622 | .891 | 8.658 | .003 | .073 | .013 | .417 | |
MRI | The tumor is reduced based on MRI. | .774 | .738 | 1.103 | .294 | 2.169 | .511 | 9.206 |
There is no change in the size of tumor based on MRI. | .774 | .957 | .655 | .418 | 2.169 | .333 | 14.145 |
MP classification | B | SE | Wald | df | Significance level | OR | 95% confidence interval | |
---|---|---|---|---|---|---|---|---|
Lower limit | Upper limit | |||||||
Luminal type A | 1.825 | .980 | 3.466 | 1 | .063 | 6.202 | .908 | 42.354 |
Luminal type B | 1.914 | .734 | 6.796 | 1 | .009 | 6.779 | 1.608 | 28.577 |
Luminal B (HER2-positive type) | -.164 | .735 | .050 | 1 | .823 | .849 | .201 | 3.587 |
HER2-positive type | -1.954 | .986 | 3.924 | 1 | .048 | .142 | .021 | .980 |
Triple negative type | 0b | . | . | 0 | . | . | . | . |
Effectiveness analysis of triple evaluation method
Clinical efficacy discrimination × two pathological classifications cross table | |||||
---|---|---|---|---|---|
Count | |||||
Two pathological classifications | Total | ||||
0 | 1 | ||||
Clinical efficacy discrimination | 69 | 0 | 0 | 69 | |
2 | 0 | 0 | 5 | 5 | |
1 | 0 | 24 | 3 | 27 | |
0 | 0 | 109 | 2 | 111 | |
Total | 69 | 133 | 10 | 212 | |
Symmetry measurement | |||||
Value | Asymptotic standard errora | Approximate Tb | Gradual significance | ||
Protocol measurement | Kappa | .716 | .039 | 14.059 | .000 |
Number of valid cases | 212 |